Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455290 | 0.92 | NR1H2 (0.41) | HSP90AA1HSP90B1TRAP1NR1H2RXRA | |
| SCHEMBL16455297 | 0.91 | NR1H2 (0.36) | HSP90AA1HSP90B1TRAP1NR1H2RXRA | |
| SCHEMBL19628302 | 0.90 | ALDH1A1 (0.36) | ALDH1A1NPSR1 | |
| SCHEMBL16455492 | 0.88 | HSP90AA1 (0.36) | HSP90AA1HSP90B1TRAP1NR1H2RXRA | |
| SCHEMBL16455600 | 0.85 | NR1H2 (0.43) | HSP90AA1HSP90B1TRAP1NR1H2RXRA | |
| SCHEMBL16455301 | 0.84 | NR1H2 (0.40) | HSP90AA1HSP90B1TRAP1NR1H2RXRA | |
| SCHEMBL16455481 | 0.83 | HSP90AA1 (0.36) | HSP90AA1HSP90B1TRAP1NR1H2RXRA | |
| SCHEMBL16455396 | 0.82 | NR1H3 (0.43) | NR1H2RXRANR1H3 | |
| SCHEMBL16452527 | 0.82 | ALDH1A1 (0.40) | ALDH1A1NPSR1 | |
| SCHEMBL16455279 | 0.81 | NR1H2 (0.45) | NR1H2RXRANR1H3ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | HSP90AA1 529/4885HSP90B1 506/4885TRAP1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.